Flamingo Pharma recalls Flucloxacillin Capsules due to incorrect patient information leaflet
The recall of Flucloxacillin Capsules due to incorrect patient information could undermine Flamingo Pharma's credibility and trust within the healthcare community. This incident necessitates close monitoring of regulatory responses and potential impacts on market positioning.
Company
Flamingo Pharma UK Ltd
Asset
Flamingo
Indication
Infectious Disease / Antibiotic
Status
Under Review
Signal Score
6.8
Signal assessment
Signal strength
moderate
Confidence level
moderate
Strategic implication
The recall of Flucloxacillin Capsules due to incorrect patient information could undermine Flamingo Pharma's credibility and trust within the healthcare community. This incident necessitates close monitoring of regulatory responses and potential impacts on market positioning.
Why it matters
The recall of Flucloxacillin Capsules due to incorrect patient information could undermine Flamingo Pharma's credibility and trust within the healthcare community. This incident necessitates close monitoring of regulatory responses and potential impacts on market positioning.
What changed
Safety Signal
Analysis
Flamingo Pharma UK Ltd has recalled certain packs of Flucloxacillin Capsules BP 500mg due to containing the incorrect patient information leaflet for Amoxicillin.
The recall of Flucloxacillin Capsules due to incorrect patient information could undermine Flamingo Pharma's credibility and trust within the healthcare community. This incident necessitates close monitoring of regulatory responses and potential impacts on market positioning.
Monitor for updates on the recall process and any regulatory actions taken by the MHRA.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.